Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antithrombin-heparin conjugate

Drug Profile

Antithrombin-heparin conjugate

Alternative Names: ATH; Covalent antithrombin-heparin complex; Heparin-antithrombin conjugate

Latest Information Update: 24 Jan 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Inflazyme Pharmaceuticals; Nonindustrial source
  • Class Antithrombotics
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Catheter thrombosis; Respiratory distress syndrome; Thrombosis

Most Recent Events

  • 27 Jul 2004 Discontinued - Preclinical for Thrombosis in Canada (unspecified route)
  • 15 Mar 2004 This compound is still in active development - (BPN-2004)
  • 15 Mar 2004 ATHt is available for licensing worldwide (www.inflazyme.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top